Thomas Trimarchi - Nov 16, 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
President and CFO
Signature
/s/ Will Solis, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Nov 16, 2025
Transactions value $
-$2,540,640
Form type
4
Date filed
11/18/2025, 07:28 PM
Previous filing
Aug 22, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Trimarchi Thomas President and CFO C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Will Solis, Attorney-in-Fact 2025-11-18 0002030813

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Tax liability -$1.42M -21.3K -5.06% $66.39 400K Nov 16, 2025 Direct F1
transaction BBIO Common Stock Sale -$660K -9.98K -2.5% $66.19 390K Nov 17, 2025 Direct F2, F3
transaction BBIO Common Stock Sale -$465K -6.96K -1.78% $66.84 383K Nov 17, 2025 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.
F2 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
F3 Represents the weighted average sale price of the shares sold from $65.575 to $66.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4 Represents the weighted average sale price of the shares sold from $66.61 to $67.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.